To sign up for our free research reports and newsletters, visit http://BeaconEquityResearch.com. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
Intrusion Inc. (OTCBB: INTZ)
Up 12.90% on Wednesday
Detailed quote: http://beaconequityresearch.com/INTZ
November 07, 2007 - Intrusion Inc. Announces Third Quarter Results
Intrusion Inc. (OTC Bulletin Board: INTZ), ("Intrusion") today announced financial results for the three months ended September 30, 2007.
Revenue for the third quarter 2007 was $0.9 million compared to $1.7 million for the third quarter 2006.
Intrusion's operating loss was $0.6 million in the third quarter 2007 compared to $0.2 million for the third quarter 2006.
Gross profit margin was 60 percent of revenue in the third quarter of 2007 compared to 55 percent of revenue in the third quarter of 2006.
Intrusion's third quarter 2007 operating expenses were $1.1 million, approximately the same as the third quarter 2006.
As of September 30, 2007, Intrusion reported cash and cash equivalents of $0.9 million, working capital of $0.4 million and debt of $0.1 million.
Intrusion closed a private placement sale of 1,190,476 shares of common stock at $0.42 per share on September 26, 2007 for a total of $500,000 in net proceeds. The stock was purchased by G. Ward Paxton, Chairman, President, and CEO. The price of the common stock was determined by taking 110% of the average closing price for the last 20 trading days up to and including the closing date of September 26, 2007.
"Our 60 percent gross profit margin in the third quarter was outstanding, and we continued our tight control of operating expenses. Revenue in the third quarter declined due to a delay in receipt of orders," stated G. Ward Paxton, Chairman, President and CEO of Intrusion.
Intrusion's management will host its regularly scheduled quarterly conference call to discuss the Company's financial and operational progress at 4:00 P.M., CST today. Interested investors can access the call at 1-800-399-2043 (if outside the
Oxis International Inc. (OTCBB: OXIS)
Up 12.50% on Wednesday
Detailed quote: http://beaconequityresearch.com/OXIS
November 07, 2007 - Oxis International Biomarker Shown Effective in Assessing Antioxidant Potential of Dietary Supplements
Oxis International Inc. (OTCBB:OXIS), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and nutraceutical and therapeutic products, announced today that CEO, Marvin S. Hausman MD., will present a poster entitled: "A Novel Method To Assess In-Vivo The Antioxidant Potential of Dietary Supplements and Foods" at the Supply Side West meeting in Las Vegas, Nevada, November 6-8, 2007.
This study describes the application of an antioxidant biomarker to measure the ability of whole food nutritional supplementation to increase the antioxidative/anti-inflammatory activity of mammalian blood. A human proof of principle clinical study revealed that the Oxis International Acute Oxidative Potential (Bioxytech AOP-490(TM)) assay could quantify antioxidant capacity within blood. The Mushroom Matrix(TM), a whole natural organic blend of powders that contain potent bioactive components, was studied in humans and horses and was shown to actively increase antioxidative/anti-inflammatory activity. Mushroom Matrix(TM) is produced by Golden Gourmet Mushrooms of San Marcos, CA.
"These studies represent an exciting first step in showing the ability of one of OXIS' antioxidant biomarkers to assess an individuals' inflammatory status and monitor attempts at nutritional supplementation," stated Marvin S. Hausman MD, CEO, Oxis International Inc. "Nutritional supplements, such as the Mushroom Matrix(TM), have the potential to correct cellular imbalance and control reactive oxygen species (ROS) associated with chronic inflammation and certain diseases such as cancer, bacterial infections, gastrointestinal disorders such as Crohn's disease, Alzheimer's Disease, heart disease and even aging. These studies suggest that proper nutritional supplementation may decrease the incidence and/or severity of these diseases."
Supply Side West is the world's largest event for healthy and innovative ingredients with 1,000+ booths. This three-day event offers food R&D and corporate management, dietary supplement executives and cosmeceuticals decision-makers the resources to develop new healthy products, learn about the latest developments in healthful ingredient applications and examine thousands of innovative ingredients.
AlphaRx (OTCBB: ALRX)
Up 9.09% on Wednesday
Detailed quote: http://beaconequityresearch.com/ALRX
November 07, 2007 - AlphaRx's Vansolin(TM) On Track To Enter Human Trials in '08
AlphaRx (OTC BB:ALRX) is pleased to announce pre-clinical data on Vansolin(TM), a Vancomycin compound encapsulated in the company's Nano Drug Delivery Platform intended for the treatment of nosocomial pneumonia.
In the recent clinical trial, mice treated with Vansolin(TM) in a Murine Model of Pneumonia showed better efficacy than Vancomycin, achieving 100% survival rate vs. 30% in the Vancomycin treatment group. With these results, Vansolin(TM) is now on track to enter into human trials in 2008.
These results support The Company's belief that encapsulating Vancomycin into AlphaRx's nano-particle formulation may increase its efficacy. According to published research papers, in vitro uptake of Vancomycin nanoparticles by white blood cells is 20 times greater than free drug. The Company anticipates that in vivo, after IV infusion, white blood cells will readily absorb Vansolin nanoparticles and transport them to the site of inflammation and infection, thereby increasing the local concentration of Vancomycin and ultimately increasing its bactericidal effect.
What's more, in the Murine Model of Pneumonia, Vancomycin encapsulated in the company's Nano Drug Delivery platform administrated by injection of 1 mg/kg, is more effective than injecting 10 mg/kg, in a conventional formulation in terms of mortality. The 90% reduction in dosage is significant, in that it may reduce potential toxicity effects of Vancomycin and may reduce treatment days from 10 days to 3 days.
Currently, the Company has four nano products in the development pipeline with an estimated annual market sales potential of over US$6.0 billion dollars.
Gulf Resources, Inc. (OTCBB: GUFR)
Up 7.32% on Wednesday
Detailed quote: http://beaconequityresearch.com/GUFR
November 07, 2007 - Gulf Resources, Inc. Receives Citibank Loan
Gulf Resources, Inc. (the "Company") (OTC Bulletin Board: GUFR) a leading producer of Bromine in China, today announced the company received a $3.66 million loan from Citibank's Shanghai branch, which bears an interest rate of approximately 6.2% annually.
The company intends to use this loan for the recently announced bromine asset purchase. The loan was secured through Shenzhen Hua Yin Guaranty and Investment Limited Liability Corporation, with common shares from the CEO, Mr. Yang, utilized as collateral.
Voyager Petroleum, Inc. (OTCBB: VYGO)
Up 6.67% on Wednesday
Detailed quote: http://beaconequityresearch.com/VYGO
November 07, 2007 - Voyager Petroleum Announces Extension of Sublease for Detroit Processing Facility
Voyager Petroleum, Inc. (OTCBB:VYGO) (Frankfurt:DXD) is pleased to announce that on October 30, 2007, it entered into an agreement extending the existing sublease for the Detroit processing facility with D.A. Stuart Company, the current Lessee, to the earliest of the date upon which Voyager or its affiliate closes on its purchase with the current owner, the termination of the Purchase Agreement for the facility without a closing or December 31, 2007.
The processing facility is located at
While discussing the facility, Sebastien DuFort, President of Voyager Petroleum, said, "We believe the plant has the capacity to accomplish our short and mid-term goals of processing used oil to fill all of our existing open purchase orders for our current customer base. The company is preparing to blend premium oils to diversify its revenue streams and to satisfy the demand for premium oils from some of our newer customers as we continue to strive to expand our product portfolio."
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has not been compensated by any of the companies covered in this release. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
